Janssen’s Sirukumab Exhibits Significant Improvements in Primary Endpoints in Japanese PIII Studies

Janssen Pharmaceutical said on April 20 that its investigational rheumatoid arthritis (RA) treatment sirukumab for patients with moderately to severely active rheumatoid RA has met its primary endpoints in two PIII clinical trials in Japanese patients. The SIRROUND program, which...read more